TMC120: Phase I/II

Tibotec reported that in a Phase I/II trial of 43 patients with HIV, 50 or 100 mg of TMC120 given twice daily for 7 days was safe. At the low dose, the number of copies/ml of HIV RNA decreased by 0.213 log and by 0.237 log at the high dose (p<0.001 versus placebo at both doses).

The company also reported in vitro data showing that TMC120, a non-nucleoside reverse transcriptase inhibitor, inhibited a variety of NNRTI-resistant strains of HIV. Its TMC126 protease inhibitor also inhibited wild type and multi-drug resistant clinical isolates of HIV in vitro. ...